Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth

Core Viewpoint - Harvard Bioscience, Inc. is consolidating its manufacturing operations to enhance efficiency, execution, and cost savings [1][3] Manufacturing Consolidation - The company will close its manufacturing facility in Holliston, MA, and transition U.S. production to Minneapolis, MN, while relocating certain operations to Germany, Sweden, and the UK [2] - The Holliston facility will remain operational throughout 2026 to ensure continuity and customer service, with the consolidation expected to be completed by Q1 2027 [3] Cost Savings and Operational Efficiency - The initiative is projected to yield approximately $3 million in cost savings in 2027 and around $4 million in annual savings thereafter [4][8] - Savings will come from reduced overhead, SKU rationalization, improved asset utilization, and a targeted reconfiguration of the workforce [4] Transition Plan - A comprehensive, phased transition plan has been implemented to prevent disruptions in order fulfillment, product quality, and technical support [3]